July 2012 Edition Vol.6, Issue 4

Spotlight on Cost of Cancer Care: Trastuzumab

Case Study: Trastuzumab

Cost of cancer care per patient is driven by dose, schedule, and changes in drug cost. Total cost of care by indication is driven by the same factors plus change in number of patients receiving therapy in a given indication.

Over 96% of trastuzumab monthly usage is coming from breast cancer. There is approximately 3% use in digestive tract tumors, specifically esophageal and stomach cancer. Month to month cost per patient has been increasing in breast cancer, with a steady 9% increase over the three year course. The large increase in total monthly cost (29%) in breast cancer is a result of the combination of steady patient growth as well as the increase in cost per patient.

Average Sales Price (ASP) is calculated based on wholesale prices 2 quarters ago. ASP+6% is used to establish the ceiling for reimbursement. ASP+6% pricing data are publicly available at www.cms.gov/McrPartBDrugAvgSalesPrice/. ASP is assumed for all graphs.

About the Contributor

IntrinsiQ, part of  AmerisourceBergen Specialty Group, is the leading provider of medical oncology clinical information systems and the premier source of oncology data and analysis in the United States.

Post a Comment

OBR Archives

To view previous issues of OBR green you can visit our archives. The entire library of OBR green articles is searchable.